Alliance Pharma plc Provides Financial Guidance for 2018; and Announces Revenues on 'See-Through' Basis for the year ended 31 December 2018
For the year ended 31 December 2018, the company reported revenues on a 'see-through' basis for 2018 were up 22% on the prior year (up 23% on a constant currency basis) at approximately £124.0 million (2017: £101.6 million, restated following the adoption of IFRS 15). Excluding acquisitions, revenues increased 4% on the prior year (4% on a constant currency basis).